VX-407

DRUG5 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Phase 1

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

CompletedNCT06345755

Vertex Pharmaceuticals IncorporatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)

Start: 2024-04-17End: 2025-06-13Updated: 2025-07-14

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

CompletedNCT07022119

Vertex Pharmaceuticals IncorporatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)

Start: 2025-06-12End: 2026-02-24Updated: 2026-03-27

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

CompletedNCT07074327

Vertex Pharmaceuticals IncorporatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)

Start: 2025-07-11End: 2026-02-27Updated: 2026-03-30

Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

Not yet recruitingNCT07792408

Vertex Pharmaceuticals IncorporatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)

Start: 2026-08-28End: 2027-03-20Target: 148Updated: 2026-08-28

Phase 2

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Active, not recruitingNCT07161037

Vertex Pharmaceuticals IncorporatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)

Start: 2025-11-19End: 2027-12-31Updated: 2026-08-11